# SciNeuro Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scineuro-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.scineuro.com
- Total disclosed funding: $153M
- Latest round: Series B (Dec 5, 2025)
- Investors on record: 7

## About

Established in 2020 and based in Rockville, US, Saishen (Shanghai) Pharmaceutical Technology Co., Ltd., trading as SciNeuro Pharmaceuticals, is a biopharmaceutical company focusing on the research and development of central nervous system drugs. The company is committed to internal innovation and global collaboration by building its CNS product portfolio. In December 2025, SciNeuro Pharmaceuticals raised USD 53 million in Series B funding co-led by returning investors Lilly Asia Ventures and ARCH Venture Partners.

The company mainly develops central nervous system drugs to treat neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD). Its R&D pipeline includes AD/Lp-PLA2, PD/alpha-synuclein, etc.

The company generates revenue through research and development, production, and sales of new drugs for the central nervous system and other related products.

The Series B funding raised in December 2025 will be used to advance the clinical development of pipelines for Alzheimer's disease, Parkinson's disease, and other conditions, as well as for team building.

## Funding rounds

- Series B, Dec 5, 2025, $53M — ARCH Venture Partners, Lilly Asia Ventures
- Series A, Dec 8, 2020, $100M — ARCH Venture Partners, Hong Shan, General Atlantic, Lilly Asia Ventures, Boyu Capital, TF Capital, Zoo Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Hong Shan — Series A
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A
- TF Capital — Series A
- Zoo Capital — Series A